← All trials
NCT05279456
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 15, 2022
- Last posted
- Aug 18, 2022
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vaxine Pty LtdLead sponsor
- Australian Respiratory and Sleep Medicine InstituteCollaborator
- Australian Respiratory and Sleep Medicine InstituteStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.